nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—Nateglinide—type 2 diabetes mellitus	0.352	1	CrCtD
Amphetamine—CARTPT—type 2 diabetes mellitus	0.256	1	CbGaD
Amphetamine—Aspartame—Nateglinide—type 2 diabetes mellitus	0.0337	0.175	CrCrCtD
Amphetamine—Lacosamide—Nateglinide—type 2 diabetes mellitus	0.0337	0.175	CrCrCtD
Amphetamine—CYP2A6—Rosiglitazone—type 2 diabetes mellitus	0.0247	0.284	CbGbCtD
Amphetamine—Phenacemide—Nateglinide—type 2 diabetes mellitus	0.0228	0.118	CrCrCtD
Amphetamine—Dextroamphetamine—Nateglinide—type 2 diabetes mellitus	0.0222	0.115	CrCrCtD
Amphetamine—Nateglinide—Ramipril—type 2 diabetes mellitus	0.0216	0.112	CrCrCtD
Amphetamine—Methamphetamine—Nateglinide—type 2 diabetes mellitus	0.0215	0.112	CrCrCtD
Amphetamine—Aspartame—Ramipril—type 2 diabetes mellitus	0.0205	0.106	CrCrCtD
Amphetamine—SLC22A3—Metformin—type 2 diabetes mellitus	0.0176	0.202	CbGbCtD
Amphetamine—L-Phenylalanine—Nateglinide—type 2 diabetes mellitus	0.0169	0.0874	CrCrCtD
Amphetamine—DRD2—Bromocriptine—type 2 diabetes mellitus	0.016	0.184	CbGbCtD
Amphetamine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00842	0.0968	CbGbCtD
Amphetamine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00777	0.0893	CbGbCtD
Amphetamine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00638	0.0733	CbGbCtD
Amphetamine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00612	0.0703	CbGbCtD
Amphetamine—CARTPT—nerve—type 2 diabetes mellitus	0.00239	0.234	CbGeAlD
Amphetamine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00131	0.128	CbGeAlD
Amphetamine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.000882	0.0863	CbGeAlD
Amphetamine—SLC6A3—nerve—type 2 diabetes mellitus	0.000615	0.0602	CbGeAlD
Amphetamine—MAOB—nerve—type 2 diabetes mellitus	0.000536	0.0524	CbGeAlD
Amphetamine—SLC6A2—nerve—type 2 diabetes mellitus	0.000496	0.0485	CbGeAlD
Amphetamine—DRD2—nerve—type 2 diabetes mellitus	0.000452	0.0442	CbGeAlD
Amphetamine—Phenformin—PRKAA1—type 2 diabetes mellitus	0.000369	0.221	CrCbGaD
Amphetamine—SLC18A2—adipose tissue—type 2 diabetes mellitus	0.000251	0.0246	CbGeAlD
Amphetamine—Phenelzine—AOC3—type 2 diabetes mellitus	0.000231	0.138	CrCbGaD
Amphetamine—CYP2A6—adipose tissue—type 2 diabetes mellitus	0.000224	0.0219	CbGeAlD
Amphetamine—MAOB—nephron tubule—type 2 diabetes mellitus	0.000209	0.0204	CbGeAlD
Amphetamine—SLC22A3—kidney—type 2 diabetes mellitus	0.000198	0.0194	CbGeAlD
Amphetamine—MAOB—cardiovascular system—type 2 diabetes mellitus	0.000188	0.0184	CbGeAlD
Amphetamine—DRD2—retina—type 2 diabetes mellitus	0.000187	0.0183	CbGeAlD
Amphetamine—MAOB—kidney—type 2 diabetes mellitus	0.000184	0.018	CbGeAlD
Amphetamine—SLC22A3—adipose tissue—type 2 diabetes mellitus	0.000179	0.0175	CbGeAlD
Amphetamine—MAOB—cortex of kidney—type 2 diabetes mellitus	0.000179	0.0175	CbGeAlD
Amphetamine—SLC18A2—liver—type 2 diabetes mellitus	0.000176	0.0172	CbGeAlD
Amphetamine—SLC22A5—retina—type 2 diabetes mellitus	0.000174	0.0171	CbGeAlD
Amphetamine—MAOB—adipose tissue—type 2 diabetes mellitus	0.000165	0.0162	CbGeAlD
Amphetamine—SLC22A5—nephron tubule—type 2 diabetes mellitus	0.000164	0.0161	CbGeAlD
Amphetamine—CYP2A6—liver—type 2 diabetes mellitus	0.000157	0.0154	CbGeAlD
Amphetamine—SLC22A5—kidney—type 2 diabetes mellitus	0.000144	0.0141	CbGeAlD
Amphetamine—SLC22A5—cortex of kidney—type 2 diabetes mellitus	0.00014	0.0137	CbGeAlD
Amphetamine—SLC22A5—adipose tissue—type 2 diabetes mellitus	0.00013	0.0127	CbGeAlD
Amphetamine—SLC22A3—liver—type 2 diabetes mellitus	0.000125	0.0123	CbGeAlD
Amphetamine—Nateglinide—ABCC8—type 2 diabetes mellitus	0.000123	0.0736	CrCbGaD
Amphetamine—MAOB—liver—type 2 diabetes mellitus	0.000116	0.0114	CbGeAlD
Amphetamine—CYP2D6—kidney—type 2 diabetes mellitus	9.31e-05	0.00911	CbGeAlD
Amphetamine—SLC22A5—liver—type 2 diabetes mellitus	9.12e-05	0.00892	CbGeAlD
Amphetamine—Nateglinide—KCNJ11—type 2 diabetes mellitus	8.66e-05	0.0518	CrCbGaD
Amphetamine—Tolazoline—ADRA2A—type 2 diabetes mellitus	6.99e-05	0.0418	CrCbGaD
Amphetamine—Decreased appetite—Glyburide—type 2 diabetes mellitus	6.95e-05	0.00114	CcSEcCtD
Amphetamine—Urticaria—Bromocriptine—type 2 diabetes mellitus	6.95e-05	0.00114	CcSEcCtD
Amphetamine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	6.94e-05	0.00113	CcSEcCtD
Amphetamine—Asthenia—Sitagliptin—type 2 diabetes mellitus	6.94e-05	0.00113	CcSEcCtD
Amphetamine—Convulsion—Orlistat—type 2 diabetes mellitus	6.92e-05	0.00113	CcSEcCtD
Amphetamine—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	6.92e-05	0.00113	CcSEcCtD
Amphetamine—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	6.92e-05	0.00113	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	6.9e-05	0.00113	CcSEcCtD
Amphetamine—Tremor—Metformin—type 2 diabetes mellitus	6.9e-05	0.00113	CcSEcCtD
Amphetamine—Chest pain—Valsartan—type 2 diabetes mellitus	6.88e-05	0.00112	CcSEcCtD
Amphetamine—Sweating—Ramipril—type 2 diabetes mellitus	6.88e-05	0.00112	CcSEcCtD
Amphetamine—Dizziness—Glipizide—type 2 diabetes mellitus	6.87e-05	0.00112	CcSEcCtD
Amphetamine—Anxiety—Valsartan—type 2 diabetes mellitus	6.86e-05	0.00112	CcSEcCtD
Amphetamine—Tension—Irbesartan—type 2 diabetes mellitus	6.82e-05	0.00111	CcSEcCtD
Amphetamine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	6.81e-05	0.00111	CcSEcCtD
Amphetamine—Chest pain—Orlistat—type 2 diabetes mellitus	6.8e-05	0.00111	CcSEcCtD
Amphetamine—Anxiety—Orlistat—type 2 diabetes mellitus	6.78e-05	0.00111	CcSEcCtD
Amphetamine—Nervousness—Irbesartan—type 2 diabetes mellitus	6.75e-05	0.0011	CcSEcCtD
Amphetamine—Dry mouth—Valsartan—type 2 diabetes mellitus	6.73e-05	0.0011	CcSEcCtD
Amphetamine—Dry mouth—Orlistat—type 2 diabetes mellitus	6.65e-05	0.00109	CcSEcCtD
Amphetamine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	6.63e-05	0.00108	CcSEcCtD
Amphetamine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	6.61e-05	0.00108	CcSEcCtD
Amphetamine—Vomiting—Glipizide—type 2 diabetes mellitus	6.61e-05	0.00108	CcSEcCtD
Amphetamine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	6.6e-05	0.00108	CcSEcCtD
Amphetamine—Dizziness—Pioglitazone—type 2 diabetes mellitus	6.58e-05	0.00108	CcSEcCtD
Amphetamine—Infection—Valsartan—type 2 diabetes mellitus	6.55e-05	0.00107	CcSEcCtD
Amphetamine—Rash—Glipizide—type 2 diabetes mellitus	6.55e-05	0.00107	CcSEcCtD
Amphetamine—Dermatitis—Glipizide—type 2 diabetes mellitus	6.55e-05	0.00107	CcSEcCtD
Amphetamine—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	6.54e-05	0.00107	CcSEcCtD
Amphetamine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	6.52e-05	0.00106	CcSEcCtD
Amphetamine—Headache—Glipizide—type 2 diabetes mellitus	6.51e-05	0.00106	CcSEcCtD
Amphetamine—Tremor—Irbesartan—type 2 diabetes mellitus	6.51e-05	0.00106	CcSEcCtD
Amphetamine—Palpitations—Metformin—type 2 diabetes mellitus	6.51e-05	0.00106	CcSEcCtD
Amphetamine—Insomnia—Gliclazide—type 2 diabetes mellitus	6.49e-05	0.00106	CcSEcCtD
Amphetamine—Infection—Orlistat—type 2 diabetes mellitus	6.48e-05	0.00106	CcSEcCtD
Amphetamine—Tension—Losartan—type 2 diabetes mellitus	6.42e-05	0.00105	CcSEcCtD
Amphetamine—Dizziness—Glimepiride—type 2 diabetes mellitus	6.41e-05	0.00105	CcSEcCtD
Amphetamine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	6.4e-05	0.00105	CcSEcCtD
Amphetamine—Dizziness—Sitagliptin—type 2 diabetes mellitus	6.39e-05	0.00104	CcSEcCtD
Amphetamine—Agitation—Irbesartan—type 2 diabetes mellitus	6.38e-05	0.00104	CcSEcCtD
Amphetamine—Somnolence—Gliclazide—type 2 diabetes mellitus	6.38e-05	0.00104	CcSEcCtD
Amphetamine—Hypertension—Metformin—type 2 diabetes mellitus	6.36e-05	0.00104	CcSEcCtD
Amphetamine—Urticaria—Glyburide—type 2 diabetes mellitus	6.35e-05	0.00104	CcSEcCtD
Amphetamine—Nervousness—Losartan—type 2 diabetes mellitus	6.35e-05	0.00104	CcSEcCtD
Amphetamine—Angioedema—Irbesartan—type 2 diabetes mellitus	6.35e-05	0.00104	CcSEcCtD
Amphetamine—Abdominal pain—Glyburide—type 2 diabetes mellitus	6.32e-05	0.00103	CcSEcCtD
Amphetamine—Dyspepsia—Gliclazide—type 2 diabetes mellitus	6.32e-05	0.00103	CcSEcCtD
Amphetamine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	6.3e-05	0.00103	CcSEcCtD
Amphetamine—Anorexia—Valsartan—type 2 diabetes mellitus	6.29e-05	0.00103	CcSEcCtD
Amphetamine—Asthenia—Bromocriptine—type 2 diabetes mellitus	6.28e-05	0.00103	CcSEcCtD
Amphetamine—Chest pain—Metformin—type 2 diabetes mellitus	6.27e-05	0.00102	CcSEcCtD
Amphetamine—Headache—Pioglitazone—type 2 diabetes mellitus	6.24e-05	0.00102	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	6.2e-05	0.00101	CcSEcCtD
Amphetamine—Fatigue—Gliclazide—type 2 diabetes mellitus	6.19e-05	0.00101	CcSEcCtD
Amphetamine—Nausea—Glipizide—type 2 diabetes mellitus	6.17e-05	0.00101	CcSEcCtD
Amphetamine—Vomiting—Glimepiride—type 2 diabetes mellitus	6.17e-05	0.00101	CcSEcCtD
Amphetamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	6.15e-05	0.001	CcSEcCtD
Amphetamine—Constipation—Gliclazide—type 2 diabetes mellitus	6.14e-05	0.001	CcSEcCtD
Amphetamine—Tremor—Losartan—type 2 diabetes mellitus	6.13e-05	0.001	CcSEcCtD
Amphetamine—Rash—Glimepiride—type 2 diabetes mellitus	6.11e-05	0.000999	CcSEcCtD
Amphetamine—Dermatitis—Glimepiride—type 2 diabetes mellitus	6.11e-05	0.000998	CcSEcCtD
Amphetamine—Phenylpropanolamine—ADRA2A—type 2 diabetes mellitus	6.11e-05	0.0365	CrCbGaD
Amphetamine—Rash—Sitagliptin—type 2 diabetes mellitus	6.09e-05	0.000995	CcSEcCtD
Amphetamine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	6.09e-05	0.000994	CcSEcCtD
Amphetamine—Erythema multiforme—Ramipril—type 2 diabetes mellitus	6.09e-05	0.000994	CcSEcCtD
Amphetamine—Headache—Glimepiride—type 2 diabetes mellitus	6.07e-05	0.000992	CcSEcCtD
Amphetamine—Headache—Sitagliptin—type 2 diabetes mellitus	6.06e-05	0.000989	CcSEcCtD
Amphetamine—Agitation—Losartan—type 2 diabetes mellitus	6.01e-05	0.000981	CcSEcCtD
Amphetamine—Hypertension—Irbesartan—type 2 diabetes mellitus	6e-05	0.00098	CcSEcCtD
Amphetamine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	5.99e-05	0.000978	CcSEcCtD
Amphetamine—Angioedema—Losartan—type 2 diabetes mellitus	5.97e-05	0.000976	CcSEcCtD
Amphetamine—Infection—Metformin—type 2 diabetes mellitus	5.97e-05	0.000975	CcSEcCtD
Amphetamine—Insomnia—Valsartan—type 2 diabetes mellitus	5.97e-05	0.000975	CcSEcCtD
Amphetamine—Chest pain—Irbesartan—type 2 diabetes mellitus	5.91e-05	0.000966	CcSEcCtD
Amphetamine—Insomnia—Orlistat—type 2 diabetes mellitus	5.9e-05	0.000963	CcSEcCtD
Amphetamine—Anxiety—Irbesartan—type 2 diabetes mellitus	5.89e-05	0.000963	CcSEcCtD
Amphetamine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	5.89e-05	0.000962	CcSEcCtD
Amphetamine—CYP2D6—liver—type 2 diabetes mellitus	5.88e-05	0.00576	CbGeAlD
Amphetamine—Dyspnoea—Valsartan—type 2 diabetes mellitus	5.88e-05	0.000961	CcSEcCtD
Amphetamine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	5.87e-05	0.000959	CcSEcCtD
Amphetamine—Somnolence—Valsartan—type 2 diabetes mellitus	5.87e-05	0.000958	CcSEcCtD
Amphetamine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	5.81e-05	0.000949	CcSEcCtD
Amphetamine—Dyspepsia—Valsartan—type 2 diabetes mellitus	5.81e-05	0.000948	CcSEcCtD
Amphetamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	5.78e-05	0.000945	CcSEcCtD
Amphetamine—Dry mouth—Irbesartan—type 2 diabetes mellitus	5.78e-05	0.000945	CcSEcCtD
Amphetamine—Palpitations—Losartan—type 2 diabetes mellitus	5.78e-05	0.000944	CcSEcCtD
Amphetamine—Nausea—Glimepiride—type 2 diabetes mellitus	5.76e-05	0.000941	CcSEcCtD
Amphetamine—Nausea—Sitagliptin—type 2 diabetes mellitus	5.74e-05	0.000938	CcSEcCtD
Amphetamine—Dyspepsia—Orlistat—type 2 diabetes mellitus	5.74e-05	0.000937	CcSEcCtD
Amphetamine—Asthenia—Glyburide—type 2 diabetes mellitus	5.74e-05	0.000937	CcSEcCtD
Amphetamine—Decreased appetite—Valsartan—type 2 diabetes mellitus	5.74e-05	0.000937	CcSEcCtD
Amphetamine—Anorexia—Metformin—type 2 diabetes mellitus	5.73e-05	0.000935	CcSEcCtD
Amphetamine—Urticaria—Gliclazide—type 2 diabetes mellitus	5.7e-05	0.000932	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	5.7e-05	0.00093	CcSEcCtD
Amphetamine—Fatigue—Valsartan—type 2 diabetes mellitus	5.69e-05	0.000929	CcSEcCtD
Amphetamine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	5.68e-05	0.000927	CcSEcCtD
Amphetamine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.68e-05	0.000927	CcSEcCtD
Amphetamine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	5.67e-05	0.000926	CcSEcCtD
Amphetamine—Decreased appetite—Orlistat—type 2 diabetes mellitus	5.67e-05	0.000926	CcSEcCtD
Amphetamine—Constipation—Valsartan—type 2 diabetes mellitus	5.64e-05	0.000921	CcSEcCtD
Amphetamine—Infection—Irbesartan—type 2 diabetes mellitus	5.63e-05	0.00092	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	5.63e-05	0.000919	CcSEcCtD
Amphetamine—Fatigue—Orlistat—type 2 diabetes mellitus	5.62e-05	0.000918	CcSEcCtD
Amphetamine—Chest pain—Losartan—type 2 diabetes mellitus	5.57e-05	0.000909	CcSEcCtD
Amphetamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.56e-05	0.000908	CcSEcCtD
Amphetamine—Anxiety—Losartan—type 2 diabetes mellitus	5.55e-05	0.000906	CcSEcCtD
Amphetamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	5.53e-05	0.000904	CcSEcCtD
Amphetamine—Rash—Bromocriptine—type 2 diabetes mellitus	5.52e-05	0.000901	CcSEcCtD
Amphetamine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.51e-05	0.0009	CcSEcCtD
Amphetamine—Tension—Ramipril—type 2 diabetes mellitus	5.5e-05	0.000898	CcSEcCtD
Amphetamine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	5.48e-05	0.000895	CcSEcCtD
Amphetamine—Headache—Bromocriptine—type 2 diabetes mellitus	5.48e-05	0.000895	CcSEcCtD
Amphetamine—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.47e-05	0.000894	CcSEcCtD
Amphetamine—Nervousness—Ramipril—type 2 diabetes mellitus	5.44e-05	0.000889	CcSEcCtD
Amphetamine—Dry mouth—Losartan—type 2 diabetes mellitus	5.44e-05	0.000889	CcSEcCtD
Amphetamine—Anorexia—Irbesartan—type 2 diabetes mellitus	5.4e-05	0.000883	CcSEcCtD
Amphetamine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.39e-05	0.000881	CcSEcCtD
Amphetamine—Dyspnoea—Metformin—type 2 diabetes mellitus	5.36e-05	0.000875	CcSEcCtD
Amphetamine—Somnolence—Metformin—type 2 diabetes mellitus	5.34e-05	0.000872	CcSEcCtD
Amphetamine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	5.34e-05	0.000871	CcSEcCtD
Amphetamine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	5.33e-05	0.000871	CcSEcCtD
Amphetamine—Infection—Losartan—type 2 diabetes mellitus	5.3e-05	0.000866	CcSEcCtD
Amphetamine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	5.29e-05	0.000864	CcSEcCtD
Amphetamine—Dyspepsia—Metformin—type 2 diabetes mellitus	5.29e-05	0.000864	CcSEcCtD
Amphetamine—Tremor—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000858	CcSEcCtD
Amphetamine—Urticaria—Valsartan—type 2 diabetes mellitus	5.24e-05	0.000856	CcSEcCtD
Amphetamine—Decreased appetite—Metformin—type 2 diabetes mellitus	5.22e-05	0.000853	CcSEcCtD
Amphetamine—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.22e-05	0.000852	CcSEcCtD
Amphetamine—Tachycardia—Losartan—type 2 diabetes mellitus	5.21e-05	0.000851	CcSEcCtD
Amphetamine—Nausea—Bromocriptine—type 2 diabetes mellitus	5.2e-05	0.000849	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.19e-05	0.000847	CcSEcCtD
Amphetamine—Fatigue—Metformin—type 2 diabetes mellitus	5.18e-05	0.000846	CcSEcCtD
Amphetamine—Urticaria—Orlistat—type 2 diabetes mellitus	5.18e-05	0.000846	CcSEcCtD
Amphetamine—Pseudoephedrine—ADRA2A—type 2 diabetes mellitus	5.16e-05	0.0309	CrCbGaD
Amphetamine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.16e-05	0.000842	CcSEcCtD
Amphetamine—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.15e-05	0.000842	CcSEcCtD
Amphetamine—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.15e-05	0.000842	CcSEcCtD
Amphetamine—Asthenia—Gliclazide—type 2 diabetes mellitus	5.15e-05	0.000841	CcSEcCtD
Amphetamine—Agitation—Ramipril—type 2 diabetes mellitus	5.15e-05	0.000841	CcSEcCtD
Amphetamine—Constipation—Metformin—type 2 diabetes mellitus	5.14e-05	0.000839	CcSEcCtD
Amphetamine—Angioedema—Ramipril—type 2 diabetes mellitus	5.12e-05	0.000837	CcSEcCtD
Amphetamine—Anorexia—Losartan—type 2 diabetes mellitus	5.09e-05	0.000831	CcSEcCtD
Amphetamine—Vomiting—Glyburide—type 2 diabetes mellitus	5.08e-05	0.00083	CcSEcCtD
Amphetamine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.05e-05	0.000826	CcSEcCtD
Amphetamine—Rash—Glyburide—type 2 diabetes mellitus	5.04e-05	0.000824	CcSEcCtD
Amphetamine—Somnolence—Irbesartan—type 2 diabetes mellitus	5.04e-05	0.000823	CcSEcCtD
Amphetamine—Dermatitis—Glyburide—type 2 diabetes mellitus	5.04e-05	0.000823	CcSEcCtD
Amphetamine—Headache—Glyburide—type 2 diabetes mellitus	5.01e-05	0.000818	CcSEcCtD
Amphetamine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.99e-05	0.000815	CcSEcCtD
Amphetamine—Palpitations—Ramipril—type 2 diabetes mellitus	4.95e-05	0.000809	CcSEcCtD
Amphetamine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	4.93e-05	0.000805	CcSEcCtD
Amphetamine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.91e-05	0.000802	CcSEcCtD
Amphetamine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.91e-05	0.000802	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	4.89e-05	0.000799	CcSEcCtD
Amphetamine—Pseudoephedrine—TNF—type 2 diabetes mellitus	4.89e-05	0.0293	CrCbGaD
Amphetamine—Fatigue—Irbesartan—type 2 diabetes mellitus	4.89e-05	0.000798	CcSEcCtD
Amphetamine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	4.86e-05	0.000794	CcSEcCtD
Amphetamine—Convulsion—Ramipril—type 2 diabetes mellitus	4.86e-05	0.000793	CcSEcCtD
Amphetamine—Constipation—Irbesartan—type 2 diabetes mellitus	4.85e-05	0.000792	CcSEcCtD
Amphetamine—Insomnia—Losartan—type 2 diabetes mellitus	4.83e-05	0.000788	CcSEcCtD
Amphetamine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	4.8e-05	0.000784	CcSEcCtD
Amphetamine—Nateglinide—PPARG—type 2 diabetes mellitus	4.8e-05	0.0287	CrCbGaD
Amphetamine—Urticaria—Metformin—type 2 diabetes mellitus	4.77e-05	0.00078	CcSEcCtD
Amphetamine—Chest pain—Ramipril—type 2 diabetes mellitus	4.77e-05	0.000779	CcSEcCtD
Amphetamine—Dyspnoea—Losartan—type 2 diabetes mellitus	4.76e-05	0.000777	CcSEcCtD
Amphetamine—Anxiety—Ramipril—type 2 diabetes mellitus	4.76e-05	0.000777	CcSEcCtD
Amphetamine—Nausea—Glyburide—type 2 diabetes mellitus	4.75e-05	0.000776	CcSEcCtD
Amphetamine—Abdominal pain—Metformin—type 2 diabetes mellitus	4.75e-05	0.000776	CcSEcCtD
Amphetamine—Dizziness—Gliclazide—type 2 diabetes mellitus	4.75e-05	0.000776	CcSEcCtD
Amphetamine—Somnolence—Losartan—type 2 diabetes mellitus	4.74e-05	0.000775	CcSEcCtD
Amphetamine—Tranylcypromine—CYP2E1—type 2 diabetes mellitus	4.74e-05	0.0284	CrCbGaD
Amphetamine—Asthenia—Valsartan—type 2 diabetes mellitus	4.73e-05	0.000773	CcSEcCtD
Amphetamine—Dyspepsia—Losartan—type 2 diabetes mellitus	4.7e-05	0.000767	CcSEcCtD
Amphetamine—Asthenia—Orlistat—type 2 diabetes mellitus	4.68e-05	0.000764	CcSEcCtD
Amphetamine—Dry mouth—Ramipril—type 2 diabetes mellitus	4.67e-05	0.000762	CcSEcCtD
Amphetamine—Decreased appetite—Losartan—type 2 diabetes mellitus	4.64e-05	0.000758	CcSEcCtD
Amphetamine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.64e-05	0.000757	CcSEcCtD
Amphetamine—Fatigue—Losartan—type 2 diabetes mellitus	4.6e-05	0.000751	CcSEcCtD
Amphetamine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000747	CcSEcCtD
Amphetamine—Vomiting—Gliclazide—type 2 diabetes mellitus	4.57e-05	0.000746	CcSEcCtD
Amphetamine—Constipation—Losartan—type 2 diabetes mellitus	4.56e-05	0.000745	CcSEcCtD
Amphetamine—Rash—Gliclazide—type 2 diabetes mellitus	4.53e-05	0.000739	CcSEcCtD
Amphetamine—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.52e-05	0.000739	CcSEcCtD
Amphetamine—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.51e-05	0.000737	CcSEcCtD
Amphetamine—Tranylcypromine—CYP1A2—type 2 diabetes mellitus	4.51e-05	0.027	CrCbGaD
Amphetamine—Urticaria—Irbesartan—type 2 diabetes mellitus	4.5e-05	0.000736	CcSEcCtD
Amphetamine—Headache—Gliclazide—type 2 diabetes mellitus	4.5e-05	0.000735	CcSEcCtD
Amphetamine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.000732	CcSEcCtD
Amphetamine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.000732	CcSEcCtD
Amphetamine—Tachycardia—Ramipril—type 2 diabetes mellitus	4.47e-05	0.000729	CcSEcCtD
Amphetamine—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.46e-05	0.000728	CcSEcCtD
Amphetamine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	4.42e-05	0.000722	CcSEcCtD
Amphetamine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.36e-05	0.000713	CcSEcCtD
Amphetamine—Dizziness—Valsartan—type 2 diabetes mellitus	4.36e-05	0.000713	CcSEcCtD
Amphetamine—Anorexia—Ramipril—type 2 diabetes mellitus	4.36e-05	0.000712	CcSEcCtD
Amphetamine—Dizziness—Orlistat—type 2 diabetes mellitus	4.31e-05	0.000704	CcSEcCtD
Amphetamine—Asthenia—Metformin—type 2 diabetes mellitus	4.31e-05	0.000704	CcSEcCtD
Amphetamine—Nausea—Gliclazide—type 2 diabetes mellitus	4.27e-05	0.000697	CcSEcCtD
Amphetamine—Phenylpropanolamine—CYP1A2—type 2 diabetes mellitus	4.24e-05	0.0254	CrCbGaD
Amphetamine—Urticaria—Losartan—type 2 diabetes mellitus	4.24e-05	0.000692	CcSEcCtD
Amphetamine—Abdominal pain—Losartan—type 2 diabetes mellitus	4.22e-05	0.000689	CcSEcCtD
Amphetamine—Body temperature increased—Losartan—type 2 diabetes mellitus	4.22e-05	0.000689	CcSEcCtD
Amphetamine—Vomiting—Valsartan—type 2 diabetes mellitus	4.19e-05	0.000685	CcSEcCtD
Amphetamine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.18e-05	0.000682	CcSEcCtD
Amphetamine—Rash—Valsartan—type 2 diabetes mellitus	4.16e-05	0.000679	CcSEcCtD
Amphetamine—Dermatitis—Valsartan—type 2 diabetes mellitus	4.16e-05	0.000679	CcSEcCtD
Amphetamine—Vomiting—Orlistat—type 2 diabetes mellitus	4.15e-05	0.000677	CcSEcCtD
Amphetamine—Insomnia—Ramipril—type 2 diabetes mellitus	4.14e-05	0.000676	CcSEcCtD
Amphetamine—Headache—Valsartan—type 2 diabetes mellitus	4.13e-05	0.000675	CcSEcCtD
Amphetamine—Diarrhoea—Metformin—type 2 diabetes mellitus	4.11e-05	0.000671	CcSEcCtD
Amphetamine—Rash—Orlistat—type 2 diabetes mellitus	4.11e-05	0.000671	CcSEcCtD
Amphetamine—Dermatitis—Orlistat—type 2 diabetes mellitus	4.11e-05	0.000671	CcSEcCtD
Amphetamine—Headache—Orlistat—type 2 diabetes mellitus	4.08e-05	0.000667	CcSEcCtD
Amphetamine—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.08e-05	0.000666	CcSEcCtD
Amphetamine—Asthenia—Irbesartan—type 2 diabetes mellitus	4.07e-05	0.000664	CcSEcCtD
Amphetamine—Somnolence—Ramipril—type 2 diabetes mellitus	4.07e-05	0.000664	CcSEcCtD
Amphetamine—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000658	CcSEcCtD
Amphetamine—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.98e-05	0.00065	CcSEcCtD
Amphetamine—Dizziness—Metformin—type 2 diabetes mellitus	3.97e-05	0.000649	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000645	CcSEcCtD
Amphetamine—Fatigue—Ramipril—type 2 diabetes mellitus	3.94e-05	0.000644	CcSEcCtD
Amphetamine—Hypersensitivity—Losartan—type 2 diabetes mellitus	3.93e-05	0.000642	CcSEcCtD
Amphetamine—Nausea—Valsartan—type 2 diabetes mellitus	3.92e-05	0.00064	CcSEcCtD
Amphetamine—Constipation—Ramipril—type 2 diabetes mellitus	3.91e-05	0.000639	CcSEcCtD
Amphetamine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.88e-05	0.000634	CcSEcCtD
Amphetamine—Methamphetamine—ADRA2A—type 2 diabetes mellitus	3.88e-05	0.0232	CrCbGaD
Amphetamine—Nausea—Orlistat—type 2 diabetes mellitus	3.87e-05	0.000632	CcSEcCtD
Amphetamine—Benzphetamine—ADRA2A—type 2 diabetes mellitus	3.85e-05	0.023	CrCbGaD
Amphetamine—Benzyl alcohol—CYP2E1—type 2 diabetes mellitus	3.83e-05	0.0229	CrCbGaD
Amphetamine—Asthenia—Losartan—type 2 diabetes mellitus	3.83e-05	0.000625	CcSEcCtD
Amphetamine—Vomiting—Metformin—type 2 diabetes mellitus	3.82e-05	0.000624	CcSEcCtD
Amphetamine—Rash—Metformin—type 2 diabetes mellitus	3.79e-05	0.000619	CcSEcCtD
Amphetamine—Dermatitis—Metformin—type 2 diabetes mellitus	3.78e-05	0.000618	CcSEcCtD
Amphetamine—Phentermine—CYP1A2—type 2 diabetes mellitus	3.78e-05	0.0226	CrCbGaD
Amphetamine—Headache—Metformin—type 2 diabetes mellitus	3.76e-05	0.000615	CcSEcCtD
Amphetamine—Dizziness—Irbesartan—type 2 diabetes mellitus	3.75e-05	0.000612	CcSEcCtD
Amphetamine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000611	CcSEcCtD
Amphetamine—Selegiline—CYP2E1—type 2 diabetes mellitus	3.68e-05	0.022	CrCbGaD
Amphetamine—Diarrhoea—Losartan—type 2 diabetes mellitus	3.65e-05	0.000596	CcSEcCtD
Amphetamine—Benzyl alcohol—CYP1A2—type 2 diabetes mellitus	3.65e-05	0.0218	CrCbGaD
Amphetamine—Urticaria—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000594	CcSEcCtD
Amphetamine—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000591	CcSEcCtD
Amphetamine—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000591	CcSEcCtD
Amphetamine—Vomiting—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000589	CcSEcCtD
Amphetamine—Rash—Irbesartan—type 2 diabetes mellitus	3.57e-05	0.000584	CcSEcCtD
Amphetamine—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.57e-05	0.000583	CcSEcCtD
Amphetamine—Nausea—Metformin—type 2 diabetes mellitus	3.57e-05	0.000583	CcSEcCtD
Amphetamine—Headache—Irbesartan—type 2 diabetes mellitus	3.55e-05	0.00058	CcSEcCtD
Amphetamine—Dizziness—Losartan—type 2 diabetes mellitus	3.53e-05	0.000576	CcSEcCtD
Amphetamine—Selegiline—CYP1A2—type 2 diabetes mellitus	3.5e-05	0.0209	CrCbGaD
Amphetamine—Vomiting—Losartan—type 2 diabetes mellitus	3.39e-05	0.000554	CcSEcCtD
Amphetamine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000551	CcSEcCtD
Amphetamine—Nausea—Irbesartan—type 2 diabetes mellitus	3.37e-05	0.00055	CcSEcCtD
Amphetamine—Rash—Losartan—type 2 diabetes mellitus	3.36e-05	0.000549	CcSEcCtD
Amphetamine—Dermatitis—Losartan—type 2 diabetes mellitus	3.36e-05	0.000549	CcSEcCtD
Amphetamine—Headache—Losartan—type 2 diabetes mellitus	3.34e-05	0.000546	CcSEcCtD
Amphetamine—Asthenia—Ramipril—type 2 diabetes mellitus	3.28e-05	0.000536	CcSEcCtD
Amphetamine—Phenelzine—CYP2E1—type 2 diabetes mellitus	3.24e-05	0.0194	CrCbGaD
Amphetamine—Nausea—Losartan—type 2 diabetes mellitus	3.17e-05	0.000518	CcSEcCtD
Amphetamine—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.13e-05	0.000511	CcSEcCtD
Amphetamine—Dizziness—Ramipril—type 2 diabetes mellitus	3.03e-05	0.000494	CcSEcCtD
Amphetamine—Tranylcypromine—CYP3A4—type 2 diabetes mellitus	2.99e-05	0.0179	CrCbGaD
Amphetamine—Vomiting—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000475	CcSEcCtD
Amphetamine—Rash—Ramipril—type 2 diabetes mellitus	2.88e-05	0.000471	CcSEcCtD
Amphetamine—Dermatitis—Ramipril—type 2 diabetes mellitus	2.88e-05	0.000471	CcSEcCtD
Amphetamine—Headache—Ramipril—type 2 diabetes mellitus	2.87e-05	0.000468	CcSEcCtD
Amphetamine—Nausea—Ramipril—type 2 diabetes mellitus	2.72e-05	0.000444	CcSEcCtD
Amphetamine—Benzyl alcohol—CYP3A4—type 2 diabetes mellitus	2.41e-05	0.0144	CrCbGaD
Amphetamine—Selegiline—CYP3A4—type 2 diabetes mellitus	2.32e-05	0.0139	CrCbGaD
Amphetamine—Nateglinide—CYP3A4—type 2 diabetes mellitus	2.07e-05	0.0124	CrCbGaD
Amphetamine—Phenelzine—CYP3A4—type 2 diabetes mellitus	2.04e-05	0.0122	CrCbGaD
Amphetamine—Nateglinide—ALB—type 2 diabetes mellitus	1.81e-05	0.0108	CrCbGaD
Amphetamine—Benzphetamine—CYP3A4—type 2 diabetes mellitus	1.77e-05	0.0106	CrCbGaD
Amphetamine—SLC22A3—Metabolism—LPL—type 2 diabetes mellitus	3.7e-06	9.44e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.7e-06	9.44e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GCG—type 2 diabetes mellitus	3.7e-06	9.43e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CALM1—type 2 diabetes mellitus	3.68e-06	9.39e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—type 2 diabetes mellitus	3.67e-06	9.36e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.66e-06	9.34e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRB3—type 2 diabetes mellitus	3.66e-06	9.34e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC2A2—type 2 diabetes mellitus	3.66e-06	9.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	3.64e-06	9.28e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOA1—type 2 diabetes mellitus	3.63e-06	9.25e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ADCY5—type 2 diabetes mellitus	3.63e-06	9.25e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GPX1—type 2 diabetes mellitus	3.61e-06	9.21e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.59e-06	9.16e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CPT1A—type 2 diabetes mellitus	3.59e-06	9.14e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTR—type 2 diabetes mellitus	3.59e-06	9.14e-05	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	3.58e-06	9.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CRHR1—type 2 diabetes mellitus	3.54e-06	9.02e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CD36—type 2 diabetes mellitus	3.52e-06	8.97e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NAMPT—type 2 diabetes mellitus	3.52e-06	8.97e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	3.51e-06	8.95e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYTB—type 2 diabetes mellitus	3.5e-06	8.93e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—OXCT1—type 2 diabetes mellitus	3.5e-06	8.93e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HBA1—type 2 diabetes mellitus	3.49e-06	8.91e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LIPC—type 2 diabetes mellitus	3.49e-06	8.91e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GCK—type 2 diabetes mellitus	3.49e-06	8.91e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPP2CA—type 2 diabetes mellitus	3.48e-06	8.86e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP11A1—type 2 diabetes mellitus	3.47e-06	8.86e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AVP—type 2 diabetes mellitus	3.46e-06	8.83e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.41e-06	8.71e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SRD5A1—type 2 diabetes mellitus	3.41e-06	8.7e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC9A1—type 2 diabetes mellitus	3.41e-06	8.7e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CETP—type 2 diabetes mellitus	3.37e-06	8.6e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—type 2 diabetes mellitus	3.34e-06	8.5e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.33e-06	8.48e-05	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—type 2 diabetes mellitus	3.31e-06	8.44e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	3.29e-06	8.4e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARA—type 2 diabetes mellitus	3.27e-06	8.34e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	3.26e-06	8.32e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSD17B3—type 2 diabetes mellitus	3.26e-06	8.3e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—STAR—type 2 diabetes mellitus	3.26e-06	8.3e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ACACA—type 2 diabetes mellitus	3.26e-06	8.3e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	3.23e-06	8.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SPRY2—type 2 diabetes mellitus	3.23e-06	8.25e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—type 2 diabetes mellitus	3.2e-06	8.15e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GNB3—type 2 diabetes mellitus	3.19e-06	8.13e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AGT—type 2 diabetes mellitus	3.17e-06	8.08e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RBP4—type 2 diabetes mellitus	3.15e-06	8.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GLP1R—type 2 diabetes mellitus	3.15e-06	8.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MMP3—type 2 diabetes mellitus	3.14e-06	8.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AVP—type 2 diabetes mellitus	3.14e-06	8.02e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—INS—type 2 diabetes mellitus	3.14e-06	7.99e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PSMD6—type 2 diabetes mellitus	3.13e-06	7.99e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SNAP25—type 2 diabetes mellitus	3.13e-06	7.99e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SREBF1—type 2 diabetes mellitus	3.13e-06	7.99e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	3.13e-06	7.98e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCC8—type 2 diabetes mellitus	3.12e-06	7.96e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CBS—type 2 diabetes mellitus	3.12e-06	7.96e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CALM1—type 2 diabetes mellitus	3.12e-06	7.94e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—type 2 diabetes mellitus	3.1e-06	7.92e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCKAR—type 2 diabetes mellitus	3.1e-06	7.91e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CTGF—type 2 diabetes mellitus	3.08e-06	7.84e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOA1—type 2 diabetes mellitus	3.07e-06	7.83e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.05e-06	7.78e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMGCR—type 2 diabetes mellitus	3.05e-06	7.77e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A2—type 2 diabetes mellitus	3e-06	7.66e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—COX2—type 2 diabetes mellitus	3e-06	7.66e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.99e-06	7.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDN1—type 2 diabetes mellitus	2.99e-06	7.63e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ADRA2A—type 2 diabetes mellitus	2.98e-06	7.61e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NCOA6—type 2 diabetes mellitus	2.95e-06	7.52e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	2.94e-06	7.51e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—UCP3—type 2 diabetes mellitus	2.9e-06	7.4e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSD11B1—type 2 diabetes mellitus	2.9e-06	7.4e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—UCP2—type 2 diabetes mellitus	2.9e-06	7.4e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—C3—type 2 diabetes mellitus	2.88e-06	7.34e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—type 2 diabetes mellitus	2.87e-06	7.33e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2E1—type 2 diabetes mellitus	2.87e-06	7.31e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	2.84e-06	7.24e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1A2—type 2 diabetes mellitus	2.83e-06	7.23e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC2A1—type 2 diabetes mellitus	2.83e-06	7.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	2.81e-06	7.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IAPP—type 2 diabetes mellitus	2.79e-06	7.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INSR—type 2 diabetes mellitus	2.78e-06	7.08e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP3A4—type 2 diabetes mellitus	2.76e-06	7.05e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3R1—type 2 diabetes mellitus	2.75e-06	7.01e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NOS3—type 2 diabetes mellitus	2.75e-06	7.01e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	2.73e-06	6.97e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PCK1—type 2 diabetes mellitus	2.73e-06	6.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.73e-06	6.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	2.72e-06	6.94e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC2A4—type 2 diabetes mellitus	2.72e-06	6.93e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GCG—type 2 diabetes mellitus	2.72e-06	6.93e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.71e-06	6.91e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—type 2 diabetes mellitus	2.7e-06	6.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	2.67e-06	6.82e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—INS—type 2 diabetes mellitus	2.65e-06	6.76e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—C3—type 2 diabetes mellitus	2.61e-06	6.66e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	2.6e-06	6.62e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HK1—type 2 diabetes mellitus	2.55e-06	6.51e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	2.53e-06	6.44e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	2.52e-06	6.42e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	2.52e-06	6.42e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—type 2 diabetes mellitus	2.51e-06	6.41e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AGT—type 2 diabetes mellitus	2.48e-06	6.33e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCKR—type 2 diabetes mellitus	2.47e-06	6.29e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—KCNJ11—type 2 diabetes mellitus	2.47e-06	6.29e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LPA—type 2 diabetes mellitus	2.47e-06	6.29e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSD3B2—type 2 diabetes mellitus	2.47e-06	6.29e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	2.45e-06	6.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	2.44e-06	6.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CYBA—type 2 diabetes mellitus	2.44e-06	6.22e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—type 2 diabetes mellitus	2.43e-06	6.2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	2.4e-06	6.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PLAT—type 2 diabetes mellitus	2.39e-06	6.09e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GHRL—type 2 diabetes mellitus	2.39e-06	6.09e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALDOB—type 2 diabetes mellitus	2.37e-06	6.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CALCA—type 2 diabetes mellitus	2.36e-06	6.02e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GNB3—type 2 diabetes mellitus	2.34e-06	5.97e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.34e-06	5.97e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMOX1—type 2 diabetes mellitus	2.33e-06	5.95e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3R1—type 2 diabetes mellitus	2.33e-06	5.93e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NOS3—type 2 diabetes mellitus	2.33e-06	5.93e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAT—type 2 diabetes mellitus	2.3e-06	5.87e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.3e-06	5.86e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	2.29e-06	5.85e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOB—type 2 diabetes mellitus	2.23e-06	5.69e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	2.22e-06	5.67e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	2.21e-06	5.64e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	2.2e-06	5.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GCG—type 2 diabetes mellitus	2.18e-06	5.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	2.18e-06	5.57e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—type 2 diabetes mellitus	2.17e-06	5.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	2.15e-06	5.48e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	2.14e-06	5.46e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LPL—type 2 diabetes mellitus	2.13e-06	5.44e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—type 2 diabetes mellitus	2.13e-06	5.42e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.12e-06	5.41e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ADCY5—type 2 diabetes mellitus	2.09e-06	5.32e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPX1—type 2 diabetes mellitus	2.08e-06	5.3e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	2.05e-06	5.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.04e-06	5.21e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CD36—type 2 diabetes mellitus	2.03e-06	5.17e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	2.01e-06	5.13e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	2.01e-06	5.13e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.01e-06	5.12e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.01e-06	5.12e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPP2CA—type 2 diabetes mellitus	2e-06	5.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	1.97e-06	5.03e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	1.96e-06	5e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	1.96e-06	5e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	1.96e-06	5e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	1.95e-06	4.97e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—type 2 diabetes mellitus	1.92e-06	4.9e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	1.91e-06	4.88e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.9e-06	4.85e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	1.89e-06	4.82e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARA—type 2 diabetes mellitus	1.88e-06	4.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.88e-06	4.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AVP—type 2 diabetes mellitus	1.86e-06	4.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.86e-06	4.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.85e-06	4.72e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.84e-06	4.69e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AGT—type 2 diabetes mellitus	1.82e-06	4.65e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.82e-06	4.65e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOB—type 2 diabetes mellitus	1.8e-06	4.58e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CALM1—type 2 diabetes mellitus	1.79e-06	4.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.79e-06	4.56e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—type 2 diabetes mellitus	1.79e-06	4.56e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOA1—type 2 diabetes mellitus	1.77e-06	4.51e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.77e-06	4.51e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	1.76e-06	4.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	1.76e-06	4.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	1.76e-06	4.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	1.73e-06	4.4e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LPL—type 2 diabetes mellitus	1.71e-06	4.37e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	1.71e-06	4.36e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.68e-06	4.28e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	1.67e-06	4.27e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.61e-06	4.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	1.61e-06	4.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	1.59e-06	4.05e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	1.59e-06	4.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.58e-06	4.03e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—type 2 diabetes mellitus	1.56e-06	3.97e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	1.55e-06	3.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—C3—type 2 diabetes mellitus	1.54e-06	3.94e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—INS—type 2 diabetes mellitus	1.53e-06	3.89e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	1.52e-06	3.89e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	1.52e-06	3.89e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.47e-06	3.75e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.47e-06	3.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AGT—type 2 diabetes mellitus	1.47e-06	3.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.44e-06	3.68e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—type 2 diabetes mellitus	1.44e-06	3.66e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LEP—type 2 diabetes mellitus	1.44e-06	3.66e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.42e-06	3.62e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—type 2 diabetes mellitus	1.4e-06	3.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.36e-06	3.46e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.34e-06	3.41e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NOS3—type 2 diabetes mellitus	1.34e-06	3.41e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.31e-06	3.35e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.31e-06	3.35e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.31e-06	3.33e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.29e-06	3.29e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.28e-06	3.27e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—type 2 diabetes mellitus	1.26e-06	3.22e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.25e-06	3.19e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	1.23e-06	3.13e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—type 2 diabetes mellitus	1.22e-06	3.12e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.22e-06	3.11e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.21e-06	3.08e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.2e-06	3.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.19e-06	3.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.19e-06	3.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.18e-06	3.01e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.17e-06	2.99e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.17e-06	2.97e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.14e-06	2.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.13e-06	2.88e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.12e-06	2.86e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.08e-06	2.75e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.08e-06	2.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.08e-06	2.74e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—type 2 diabetes mellitus	1.07e-06	2.73e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.06e-06	2.69e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.02e-06	2.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.01e-06	2.58e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.01e-06	2.56e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1e-06	2.56e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	9.91e-07	2.53e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.23e-07	2.35e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.14e-07	2.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.08e-07	2.32e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	8.73e-07	2.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.64e-07	2.2e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	8.56e-07	2.18e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.55e-07	2.18e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.38e-07	2.14e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	7.96e-07	2.03e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	7.85e-07	2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.76e-07	1.98e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	7.51e-07	1.91e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	7.51e-07	1.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.12e-07	1.82e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.98e-07	1.78e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	6.87e-07	1.75e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—type 2 diabetes mellitus	6.16e-07	1.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.36e-07	1.37e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.95e-07	1.26e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.45e-07	8.8e-06	CbGpPWpGaD
